WCLC 2026: vídeos e entrevistas
65 vídeos do WCLC 2026 publicados por IASLC, Oncology Brothers, VJOncology. Atualizado em 20/11/2026.
Zidesamtinib in TKI-naïve patients with ROS1+ NSCLC: insights from the ARROS-1 trialVJOncology · 16/10/2026 · 4:59 · apoio da indústria
2026 Cancer Care Team AwardsIASLC · 15/10/2026 · 3:15
Luis Montuenga | Adi F. Gazdar IASLC Merit Award 2026IASLC · 15/10/2026 · 3:30
Dr. Karen Kelly Provides an Update Live from 2026 WCLCIASLC · 15/10/2026 · 3:49
Lung cancer incidence in women in the MENA region: insights from the GLOBOCAN databaseVJOncology · 06/10/2026 · 3:58 · apoio da indústria
Concerns with integrating AI into surgical practice for patients with lung cancerVJOncology · 06/10/2026 · 1:04 · apoio da indústria
Applications of AI to improve surgical outcomes for patients with lung cancerVJOncology · 06/10/2026 · 1:17 · apoio da indústria
The role of AI in surgery for patients with lung cancerVJOncology · 06/10/2026 · 1:04 · apoio da indústria
Updated PALOMA-2 results: subcutaneous amivantamab + lazertinib in NSCLCVJOncology · 06/10/2026 · 1:10 · apoio da indústria
Treatment of oligometastatic disease in patients with molecularly targetable alterationsVJOncology · 06/10/2026 · 1:48 · apoio da indústria
Subgroup and toxicity insights from AMIGO-1 in in EGFRm NSCLCVJOncology · 06/10/2026 · 1:22 · apoio da indústria
AMIGO-1: pemetrexed, amivantamab and lazertinib in metastatic EGFRm NSCLCVJOncology · 06/10/2026 · 1:50 · apoio da indústria
PAPILLON: OS findings of amivantamab & chemotherapy in EGFR exon 20 ins-NSCLCVJOncology · 06/10/2026 · 7:19 · apoio da indústria
Ultra-sensitive MRD assays in NSCLC to monitor response to treatment and surgeryVJOncology · 06/10/2026 · 4:01 · apoio da indústria
Opportunities and limitations of AI-driven incidental pulmonary nodule detectionVJOncology · 06/10/2026 · 1:18 · apoio da indústria
AI-driven incidental pulmonary nodule program to increase lung cancer detectionVJOncology · 06/10/2026 · 3:55 · apoio da indústria
World Lung Conference Highlights from #WCLC26 with Dr. Christine LovlyOncology Brothers · 06/10/2026 · 1:38 · apoio da indústria
TAISHAN-302: tambotatug pelitecan versus topotecan in relapsed SCLCVJOncology · 05/10/2026 · 1:39 · apoio da indústria
ARTEMIS-008: risvutatug rezetecan versus topotecan in relapsed SCLCVJOncology · 05/10/2026 · 1:31 · apoio da indústria
WCLC 2026 Highlights: MAVERICK, ADAURA, HARMONi, PAPILLON, DESTINY-Lung04 with Dr. Christine LovlyOncology Brothers · 05/10/2026 · 19:22 · apoio da indústria
Brazil’s tobacco control efforts and primary lung cancer preventionVJOncology · 29/09/2026 · 3:28 · apoio da indústria
Community health workers improve lung cancer prevention in BrazilVJOncology · 29/09/2026 · 2:45 · apoio da indústria
Improving early lung cancer diagnosis in Brazil with mobile unitsVJOncology · 29/09/2026 · 2:23 · apoio da indústria
Actionable alterations and targeted therapies in younger patients with lung cancerVJOncology · 22/09/2026 · 1:16 · apoio da indústria
Younger patients with lung cancer show distinct genomic and immune phenotype alterationsVJOncology · 22/09/2026 · 3:10 · apoio da indústria
ctDNA and ctRNA for the detection of actionable fusions in NSCLCVJOncology · 22/09/2026 · 2:10 · apoio da indústria
Amivantamab plus lazertinib as a new standard-of-care for metastatic EGFRm NSCLC?VJOncology · 22/09/2026 · 1:02 · apoio da indústria
AI tools for clinical advice in NSCLC without actionable mutationsVJOncology · 22/09/2026 · 2:16 · apoio da indústria
COPERNICUS: safety of subcutaneous amivantamab plus lazertinib in EGFRm NSCLCVJOncology · 22/09/2026 · 3:23 · apoio da indústria
Lung cancer highlights from WCLC 2026VJOncology · 18/09/2026 · 19:29 · apoio da indústria
STARLET: osimertinib alone or with SRS for EGFRm lung cancer with brain metastasisVJOncology · 17/09/2026 · 2:30 · apoio da indústria
Factors affecting lung cancer risk in areas outside of the US and EuropeVJOncology · 17/09/2026 · 1:23 · apoio da indústria
Applicability of international lung cancer screening guidelines in ZimbabweVJOncology · 17/09/2026 · 3:00 · apoio da indústria
Association between BMI and prognosis in NSCLC patients treated with TKIsVJOncology · 17/09/2026 · 1:15 · apoio da indústria
Whole-transcriptomic profiling to identify biomarkers for metastasis in early-stage NSCLCVJOncology · 17/09/2026 · 1:15 · apoio da indústria
Clinical, pathologic, genomic and immunophenotypic characterization of KRAS G12V NSCLCVJOncology · 17/09/2026 · 1:54 · apoio da indústria
Female sex associated with improved survival in patients with NSCLC treated with ALK TKIsVJOncology · 17/09/2026 · 1:39 · apoio da indústria
Driver mutations increase survival in never-smokers with lung cancerVJOncology · 17/09/2026 · 1:04 · apoio da indústria
DNA-PKcs inhibition activates innate immunity in small cell lung cancerVJOncology · 16/09/2026 · 2:56 · apoio da indústria
Targeting macrophages to prevent neuroendocrine transformation in lung cancerVJOncology · 16/09/2026 · 1:50 · apoio da indústria
Immune suppression drives neuroendocrine transformation in EGFRm lung cancerVJOncology · 16/09/2026 · 3:31 · apoio da indústria
TROP2-high tumors are associated with cold immune signaturesVJOncology · 16/09/2026 · 1:00 · apoio da indústria
TROP2 protein and RNA expression in NSCLC tissueVJOncology · 16/09/2026 · 2:02 · apoio da indústria
Age does not define survival outcomes in lung cancerVJOncology · 16/09/2026 · 2:04 · apoio da indústria
Lung cancer incidence in never-smoking Asian women with a family history of lung cancerVJOncology · 16/09/2026 · 2:38 · apoio da indústria
Could liquid biopsy improve follow-up of lung cancer with indeterminate findings?VJOncology · 16/09/2026 · 1:04 · apoio da indústria
RISP: cytisine for smoking cessation in patients over the age of 65VJOncology · 16/09/2026 · 1:48 · apoio da indústria
IASLC 2026 World Conference on Lung Cancer--Tuesday, September 15th Press BriefingIASLC · 15/09/2026 · 45:10
Chemoimmunotherapy improves survival in PD-L1 1–49% NSCLCVJOncology · 15/09/2026 · 2:49 · apoio da indústria
Class 3 BRAF alterations predict poor immunotherapy outcomes in NSCLCVJOncology · 15/09/2026 · 4:34 · apoio da indústria
Racial and ethnic disparities in NSCLC molecular profiles and survivalVJOncology · 15/09/2026 · 4:00 · apoio da indústria
MTAP deletion and PRMT5 expression predict poor outcomes in NSCLCVJOncology · 15/09/2026 · 3:34 · apoio da indústria
Small cell lung cancer highlights at WCLC 2026VJOncology · 15/09/2026 · 1:36 · apoio da indústria
CHIMERA: perioperative chemoimmunotherapy in mesotheliomaVJOncology · 15/09/2026 · 2:04 · apoio da indústria
IASLC 2026 World Conference on Lung Cancer Monday, September 14th Press BriefingIASLC · 14/09/2026 · 1:06:04
CTCs in CSF could predict response and prognosis in leptomeningeal diseaseVJOncology · 14/09/2026 · 3:11 · apoio da indústria
Biallelic inactivation of KEAP1/STK11 predicts response to checkpoint blockade in NSCLCVJOncology · 14/09/2026 · 3:08 · apoio da indústria
Phase I dose expansion results of izalontamab brenitecan in EGFRm NSCLCVJOncology · 14/09/2026 · 1:03 · apoio da indústria
How will izalontamab brenitecan fit in the lung cancer treatment landscape?VJOncology · 14/09/2026 · 1:00 · apoio da indústria
NSCLC with EGFR exon 20 insertions at WCLC 2026: PAPILLON & REZILIENT 3VJOncology · 14/09/2026 · 3:41 · apoio da indústria